---
title: "Ascentage Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279081736.md"
description: "Ascentage Pharma Group International has scheduled a board meeting for March 25, 2026, to approve its annual results for the financial year ending December 31, 2025, and to consider declaring a final dividend. This meeting is crucial for aligning financial reporting and shareholder returns with the company's strategic objectives. The latest analyst rating for Ascentage Pharma (HK:6855) is a Hold, with a price target of HK$46.00. The company focuses on developing innovative therapies for oncology and other diseases, with a current market cap of HK$17.49B."
datetime: "2026-03-13T15:09:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279081736.md)
  - [en](https://longbridge.com/en/news/279081736.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279081736.md)
---

# Ascentage Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest update is out from Ascentage Pharma Group International ( (HK:6855) ).

Ascentage Pharma Group International has scheduled a board meeting for March 25, 2026, to review and approve the group’s annual results for the financial year ended December 31, 2025. The board will also consider the declaration of a final dividend, signaling a potential distribution of profits to shareholders and offering an indication of the company’s financial performance and capital allocation strategy.

The meeting underscores routine yet important governance procedures for the Hong Kong-listed drug developer, which relies on board oversight to align financial reporting and shareholder returns with its long-term strategic objectives. Any dividend decision could influence investor sentiment and reflect management’s confidence in the company’s operational momentum and cash position following the 2025 reporting period.

The most recent analyst rating on (HK:6855) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.

**More about Ascentage Pharma Group International**

Ascentage Pharma Group International is a Cayman Islands incorporated biopharmaceutical company listed in Hong Kong, focusing on the research and development of innovative oncology and other disease therapies. The group operates through subsidiaries including operations in Suzhou, China, and is overseen by a board comprising executive, non-executive, and independent non-executive directors with extensive scientific and governance credentials.

**Average Trading Volume:** 2,004,131

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$17.49B

For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [06855.HK](https://longbridge.com/en/quote/06855.HK.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [520500.CN](https://longbridge.com/en/quote/520500.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)

## Related News & Research

- [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md)
- [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md)
- [CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)](https://longbridge.com/en/news/282769048.md)
- [Everest’s US$250 million buy signals rising global appetite for China biotech](https://longbridge.com/en/news/282130717.md)
- [TransThera Sciences Launches Discounted HK$290 Million H-Share Placement](https://longbridge.com/en/news/282767094.md)